施贵宝(BMY.US)新药Camzyos三期临床告捷有望成首款青少年罕见心脏病疗法_老虎社区_美港股上老虎

施贵宝(BMY.US)新药Camzyos三期临床告捷有望成首款青少年罕见心脏病疗法

智通财经03-30

智通财经APP获悉，施贵宝(BMY.US)于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。此项研究针对患有梗阻性肥厚型心肌病的青少年患者。该疾病会导致心脏射血阻力升高，引发严重临床症状。目前，尚无专门获批用于未成年患者的针对性疗法，临床医生通常只能沿用成人治疗方案。在这项三期试验中，相较于安慰剂组，Camzyos可显著...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2623362213?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-30 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623362213","market":"hk","top_or_hot":-1,"title":"施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，施贵宝(BMY.US)于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。此项研究针对患有梗阻性肥厚型心肌病的青少年患者。该疾病会导致心脏射血阻力升高，引发严重临床症状。目前，尚无专门获批用于未成年患者的针对性疗法，临床医生通常只能沿用成人治疗方案。在这项三期试验中，相较于安慰剂组，Camzyos可显著...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421511.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 10:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1421511.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，施贵宝(BMY.US)于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。此项研究针对患有梗阻性肥厚型心肌病的青少年患者。该疾病会导致心脏射血阻力升高，引发严重临床症状。目前，尚无专门获批用于未成年患者的针对性疗法，临床医生通常只能沿用成人治疗方案。在这项三期试验中，相较于安慰剂组，Camzyos可显著...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421511.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1074936037.SGD","symbol_name":"JPMorgan Funds - US Value A (acc) SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1421511.html","article_id":"2623362213","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623362213","pubTimestamp":1774836292,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，施贵宝于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。施贵宝表示，基于该药物已在成人患者中获批应用的基础，本次数据支持Camzyos拓展至青少年适应症的开发潜力。若该适应症最终获得监管机构批准，Camzyos将为这类患病青少年提供全新治疗选择，有望改善临床症状，并降低患者接受侵入性手术治疗的需求。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4007":"制药","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BMY":"施贵宝","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","BK4588":"碎股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0237698245.USD":"富达环球地产基金A","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC"},"translate_title":"Squibb's (BMY.US) new drug Camzyos Phase III clinical success is expected to become the first rare heart disease therapy for adolescents","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1.5},"content_text":"智通财经APP获悉，施贵宝(BMY.US)于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。此项研究针对患有梗阻性肥厚型心肌病的青少年患者。该疾病会导致心脏射血阻力升高，引发严重临床症状。目前，尚无专门获批用于未成年患者的针对性疗法，临床医生通常只能沿用成人治疗方案。在这项三期试验中，相较于安慰剂组，Camzyos可显著降低引发心脏梗阻的室内压力。经过约六个月治疗，受试者在心脏功能、临床症状及运动耐量等方面均出现明显改善。参与研究的医学专家表示，该研究成果是该领域的重要突破。费城儿童医院的Joseph Rossano指出，对于治疗选择极为有限的这一患者群体而言，此次研究发现具有里程碑式的意义。该试验共纳入44名12至17岁的患者。接受Camzyos治疗的受试者，多项心脏功能指标均呈现持续改善，包括心脏梗阻程度缓解及心脏结构的积极变化。药物安全性数据同样表现良好。用药组与安慰剂组的不良反应发生率相近，研究期间未发现新增安全风险信号。施贵宝表示，基于该药物已在成人患者中获批应用的基础，本次数据支持Camzyos拓展至青少年适应症的开发潜力。公司将继续推进相关研究，并在未来公布长期随访数据。若该适应症最终获得监管机构批准，Camzyos将为这类患病青少年提供全新治疗选择，有望改善临床症状，并降低患者接受侵入性手术治疗的需求。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}